DGM
Darwin Global Management Portfolio holdings
AUM
$2.38B
This Quarter Return
+21.69%
1 Year Return
+81.43%
3 Year Return
+6,053.69%
5 Year Return
–
10 Year Return
–
AUM
$543M
AUM Growth
+$543M
(-12%)
Cap. Flow
-$93.1M
Cap. Flow
% of AUM
-17.14%
Top 10 Holdings %
Top 10 Hldgs %
99.78%
Holding
17
New
5
Increased
3
Reduced
4
Closed
5
Top Buys
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$41.2M |
| 2 |
BioNTech
BNTX
|
$36.3M |
| 3 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$10.6M |
| 4 |
Invivyd
IVVD
|
$3.66M |
| 5 |
Vir Biotechnology
VIR
|
$1.97M |
Top Sells
| 1 |
Intellia Therapeutics
NTLA
|
$149M |
| 2 |
Beam Therapeutics
BEAM
|
$16.3M |
| 3 |
ESSA Pharma
EPIX
|
$5.96M |
| 4 |
Keros Therapeutics
KROS
|
$4.43M |
| 5 |
Relay Therapeutics
RLAY
|
$4.38M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
XLRN
1
DELISTED
Acceleron Pharma Inc.
XLRN
| $344M | 63.36% | 2,000,000 +239,654 | +14% | +$41.2M |
|
|
2
Intellia Therapeutics
NTLA
$1.22B
| $101M | 18.57% | 752,024 -1,107,902 | -60% | -$149M |
|
|
3
BioNTech
BNTX
$24B
| $36.3M | 6.68% | +132,932 | New | +$36.3M |
|
4
Fate Therapeutics
FATE
$120M
| $20.9M | 3.85% | 353,250 +17,332 | +5% | +$1.03M |
|
|
INBX
5
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $18.1M | 3.33% | 542,586 +317,106 | +141% | +$10.6M |
|
6
BridgeBio Pharma
BBIO
$9.89B
| $11.9M | 2.19% | 253,692 -83,125 | -25% | -$3.9M |
|
|
7
Invivyd
IVVD
$204M
| $3.66M | 0.67% | +86,528 | New | +$3.66M |
|
8
Aclaris Therapeutics
ACRS
$209M
| $2.87M | 0.53% | 159,393 -90,607 | -36% | -$1.63M |
|
|
9
Vir Biotechnology
VIR
$686M
| $1.97M | 0.36% | +45,311 | New | +$1.97M |
|
|
VERV
10
DELISTED
Verve Therapeutics
VERV
| $1.29M | 0.24% | 27,397 -75,616 | -73% | -$3.55M |
|
11
Fulcrum Therapeutics
FULC
$351M
| $959K | 0.18% | +33,997 | New | +$959K |
|
|
JBIO
12
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $262K | 0.05% | +12,484 | New | +$262K |
|
|
13
Beam Therapeutics
BEAM
$1.66B
| – | – | -126,985 | Closed | -$16.3M |
|
|
14
ESSA Pharma
EPIX
$11.4M
| – | – | -208,524 | Closed | -$5.96M |
|
15
Generation Bio
GBIO
$40.4M
| – | – | -10,738 | Closed | -$289K |
|
|
16
Keros Therapeutics
KROS
$618M
| – | – | -104,186 | Closed | -$4.43M |
|
|
17
Relay Therapeutics
RLAY
$619M
| – | – | -119,775 | Closed | -$4.38M |
|